Dublin, April 08, 2022 (GLOBE NEWSWIRE) -- The "North America Monoclonal Antibodies Market 2020-2030 by Source, Category, Production Type, Application, End User, and Country: Trend Forecast and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.
The North American monoclonal antibodies market is projected to grow by 10.4% annually in the forecast period and reach $133.4 billion by 2030, driven by the increasing incidences of new cancer cases and other diseases, growth in geriatric population, increasing pharmaceutical R&D spending, upsurge in healthcare expenditure, and the rising adoption of cost-efficient biosimilar monoclonal antibodies.
This report is based on a comprehensive research of the entire North America monoclonal antibodies market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19
In-depth qualitative analyses include identification and investigation of the following aspects:
- Market Structure
- Growth Drivers
- Restraints and Challenges
- Emerging Product Trends & Market Opportunities
- Porter's Fiver Forces
The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America monoclonal antibodies market in every aspect of the classification from perspectives of Source, Category, Production Type, Application, End User, and Country.
Based on Source, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
- Human
- Humanized
- Chimeric
- Murine
Based on Category, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
- Branded mAbs
- Biosimilar mAbs
Based on Production Type, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
- In Vitro Production
- In Vivo Production
Based on Application, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
- Cancer
- Breast Cancer
- Colorectal Cancer
- Lung Cancer
- Ovarian Cancer
- Other Cancer Types
- Autoimmune Diseases
- Inflammatory Diseases
- Infectious Diseases
- Other Applications
By End User, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
- Hospitals
- Research Institutes
- Other End Users
Geographically, the following national/local markets are fully investigated:
- U.S.
- Canada
- Mexico
For each key country, detailed analysis and data for annual revenue ($ bn) are available for 2019-2030. The breakdown of key national markets by Source, Application, and End User over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Key Topics Covered:
1 Introduction
2 Market Overview and Dynamics
2.1 Market Size and Forecast
2.1.1 Impact of Covid-19 on World Economy
2.1.2 Impact of Covid-19 on the Market
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter's Five Forces Analysis
3 Segmentation of North America Market by Source
3.1 Market Overview by Source
3.2 Human
3.3 Humanized
3.4 Chimeric
3.5 Murine
4 Segmentation of North America Market by Category
4.1 Market Overview by Category
4.2 Branded Mabs
4.3 Biosimilar Mabs
5 Segmentation of North America Market by Production Type
5.1 Market Overview by Production Type
5.2 in Vitro Production
5.3 in Vivo Production
6 Segmentation of North America Market by Application
6.1 Market Overview by Application
6.2 Cancer
6.2.1 Breast Cancer
6.2.2 Colorectal Cancer
6.2.3 Lung Cancer
6.2.4 Ovarian Cancer
6.2.5 Other Cancer Types
6.3 Autoimmune Diseases
6.4 Inflammatory Diseases
6.5 Infectious Diseases
6.6 Other Applications
7 Segmentation of North America Market by End-user
7.1 Market Overview by End-user
7.2 Hospitals
7.3 Research Institutes
7.4 Other End-users
8 North America Market 2019-2030 by Country
8.1 Overview of North America Market
8.2 U.S.
8.3 Canada
8.4 Mexico
9 Competitive Landscape
9.1 Overview of Key Vendors
9.2 New Product Launch, Partnership, Investment, and M&A
9.3 Company Profiles
- Abbott Laboratories
- Abbvie, Inc.
- Amgen Inc.
- Astrazeneca plc
- Bayer Ag
- Bristol-Myers Squibb Company
- Eli Lilly
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc
- Johnson & Johnson
- Merck & Co. Inc.
- Mylan N.V
- Norvatis Ag
- Pfizer
- Sanofi S.A.
- Related Reports
For more information about this report visit https://www.researchandmarkets.com/r/vw6nc9
Attachment
